Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Aug 11:7:306.
doi: 10.3389/fimmu.2016.00306. eCollection 2016.

Scrutinizing the Biomarkers for the Neglected Chagas Disease: How Remarkable!

Rosa T Pinho  1 , Mariana C Waghabi  2 , Fabíola Cardillo  3 , José Mengel  4 , Paulo R Z Antas  1
Affiliations
Review

Scrutinizing the Biomarkers for the Neglected Chagas Disease: How Remarkable!

Rosa T Pinho et al. Front Immunol. .

Abstract

Biomarkers or biosignature profiles have become accessible over time in population-based studies for Chagas disease. Thus, the identification of consistent and reliable indicators of the diagnosis and prognosis of patients with heart failure might facilitate the prioritization of therapeutic management to those with the highest chance of contracting this disease. The purpose of this paper is to review the recent state and the upcoming trends in biomarkers for human Chagas disease. As an emerging concept, we propose a classification of biomarkers based on plasmatic-, phenotype-, antigenic-, genetic-, and management-related candidates. The available data revisited here reveal the lessons learned thus far and the existing challenges that still lie ahead to enable biomarkers to be employed consistently in risk evaluation for this disease. There is a strong need for biomarker validation, particularly for biomarkers that are specific to the clinical forms of Chagas disease. The current failure to achieve the eradication of the transmission of this disease has produced determination to solve this validation issue. Finally, it would be strategic to develop a wide variety of biomarkers and to test them in both preclinical and clinical trials.

Keywords: Chagas disease; biomarkers for immune responsiveness; clinical forms; human experimentation; mini review.

PubMed Disclaimer

References

    1. WHO. Chagas Disease (American trypanosomiasis) Fact Sheet 340. World Health Organization; (2012). Available from: http://www.who.int/mediacentre/factsheets/fs340/en/index.html
    1. Punukollu G, Gowda RM, Khan IA, Navarro VS, Vasavada BC. Clinical aspects of the Chagas’ heart disease. Int J Cardiol (2007) 115:279–83.10.1016/j.ijcard.2006.03.004 - DOI - PubMed
    1. Pinazo MJ, Canas E, Elizalde JI, Garcia M, Gascon J, Gimeno F, et al. Diagnosis, management and treatment of chronic Chagas’ gastrointestinal disease in areas where Trypanosoma cruzi infection is not endemic. Gastroenterol Hepatol (2010) 33:191–200.10.1016/j.gastrohep.2009.07.009 - DOI - PubMed
    1. Wang Y, Moreira Mda C, Heringer-Walther S, Ebermann L, Schultheiss HP, Wessel N, et al. Plasma ACE 2 activity is an independent prognostic marker in Chagas’ disease and equally potent as BNP. J Card Fail (2010) 16(2):157–63.10.1016/j.cardfail.2009.09.005 - DOI - PubMed
    1. Requena-Mendez A, Lopez MC, Angheben A, Izquierdo L, Ribeiro I, Pinazo MJ, et al. Evaluating Chagas’ disease progression and cure through blood-derived biomarkers: a systematic review. Expert Rev Anti Infect Ther (2013) 11(9):957–76.10.1586/14787210.2013.824718 - DOI - PubMed